Livanova (LIVN) Q1 2026: Cardiopulmonary Output to Rise 60% by 2030 as Market Share Jumps
Livanova’s Q1 results showcase accelerating market share gains in cardiopulmonary and robust pricing power in epilepsy, underpinned by improved reimbursement and clinical evidence. Strategic investments in manufacturing, digital health, and OSA innovation set the stage for sustained growth and margin durability. Guidance raises reflect management’s confidence in core and pipeline execution, but operational risks and external cost pressures remain key watchpoints.
Summary
- Cardiopulmonary Manufacturing: Expanded capacity and new lines drive double-digit output growth and market share gains.
- Epilepsy Reimbursement Shift: Improved U.S. rates and clinical data enable pricing power and broadened adoption.
- OSA Launch Readiness: Regulatory and clinical milestones advance entry into the high-growth sleep apnea market for 2027.
Business Overview
Livanova is a global medical technology company specializing in advanced therapeutic solutions for cardiovascular and neuromodulation diseases. The company generates revenue through two primary segments: Cardiopulmonary, which includes heart-lung machines, oxygenators, and related consumables for cardiac surgery; and Neuromodulation, focused on implantable devices and therapies for epilepsy and difficult-to-treat depression. A third growth vector is emerging in Obstructive Sleep Apnea (OSA), leveraging proprietary hypoglossal nerve stimulation (HGNS) technology. Livanova’s revenue is geographically diversified, with commercial execution and innovation as core business levers.
Performance Analysis
Livanova delivered 11% revenue growth in Q1 2026, with strength across all major product lines and regions. Cardiopulmonary revenue rose 14%, driven by high teens growth in heart-lung machines and mid-teens gains in consumables, reflecting both underlying demand and favorable price/mix. Notably, market share in oxygenators expanded from 30% to 40% over two years, an uncommon feat in a mature segment. Management attributes this to increased manufacturing output and capacity expansion, including a new line going live in H2 2026.
Epilepsy revenue increased 8% year over year, with U.S. growth at 7% and Europe/rest of world up 12%. Recent Medicare reimbursement changes for VNS therapy procedures (up ~48% for new implants) have immediately improved realized pricing and reduced volume discounting, supporting not just near-term margin but also laying a foundation for broader therapy adoption. Gross margin remained strong at 68%, with higher volumes and pricing offset by currency and product mix shifts. Operating income margin held steady at 20%, balancing R&D investment in OSA with ongoing leverage in core businesses.
- Cardiopulmonary Output Acceleration: New manufacturing lines and improved third-party supply underpin a low double-digit increase in 2026 output, with further ramp expected through 2030.
- Epilepsy Pricing Power: Favorable reimbursement and clinical data have begun to reduce discounting and strengthen patient funnel dynamics.
- R&D and CapEx Allocation: Q1 saw elevated R&D (13% of revenue) and capital spend ($14M), primarily for OSA and next-gen oxygenator scale-up.
Cash flow was seasonally low due to bonus payouts and working capital, but management expects conversion to normalize, supporting capital allocation priorities. The updated full-year guidance reflects raised expectations for both core segments.
Executive Commentary
"Our core businesses continue to serve as both the drivers of current performance and enablers of discipline, investment and innovation... We expect these investments to fuel the long term durability of our core performance, as well as expansion into high growth, high margin markets to build a more sustainable financial profile for value creation over time."
Vladimir Makatsaria, Chief Executive Officer
"We now forecast 2026 revenue growth between seven and 8% on a constant currency basis, up from six to 7% previously. We continue to expect the impact of foreign currency to be a tailwind of approximately 1% based on current exchange rates."
Alex Schwartzberg, Chief Financial Officer
Strategic Positioning
1. Cardiopulmonary Capacity and Market Share
Livanova is executing a bold expansion of oxygenator and heart-lung machine output, targeting a 60% increase in oxygenator capacity by 2030 and aiming for an 800 basis point jump in market share. The company is leveraging both internal manufacturing investments and improved third-party supply relationships, positioning itself as the clear leader while competitors pull back on capacity and innovation. This “share as a growth lever” strategy is rare in mature medtech markets and provides a durable volume and pricing tailwind.
2. Epilepsy: Reimbursement and Clinical Evidence Tailwind
Recent U.S. Medicare reimbursement hikes for VNS therapy have immediately improved price realization and reduced discounting. Combined with the dissemination of robust core VNS study data, Livanova is seeing early signs of both higher procedure volume and pipeline expansion. The company is working to activate lapsed accounts and open new centers, with the full volume impact expected to materialize in the second half and beyond.
3. OSA Platform and Innovation Pipeline
Regulatory and clinical milestones for the Aura 6000 HGNS system establish Livanova as a credible future entrant in the OSA market. The FDA approval and publication of the Osprey randomized controlled trial (RCT) results provide a differentiated evidence base. The company is preparing for a limited launch in 2027, with next-gen MRI-compatible devices and advanced algorithms (PolySync) designed to further expand patient response rates and address broader populations.
4. Digital Health and Connected Care
Livanova’s rollout of a cloud-based clinician portal and app for epilepsy marks a strategic move to digitize care pathways, enabling remote titration and real-time patient insights. The unified digital platform is expected to be a long-term enabler for both patient engagement and operational efficiency, with broader rollout aligned to next-gen device launches in 2027.
5. Capital Allocation and Margin Discipline
Despite ongoing investment in R&D and manufacturing, management is focused on maintaining operating margins above 20% and achieving 80% free cash flow conversion by 2028. Early debt repayment and disciplined CapEx signal a conservative approach to balance sheet management, even as growth investments accelerate.
Key Considerations
This quarter signals Livanova’s ability to both defend and expand its core businesses while investing for future growth. The interplay between pricing, innovation, and manufacturing scale is central to its durable growth thesis.
Key Considerations:
- Market Share Momentum: Oxygenator and HLM share gains in a consolidating market provide outsized leverage on both volume and pricing.
- Reimbursement-Driven Growth: U.S. Medicare changes for VNS therapy are reducing barriers and catalyzing broader adoption in epilepsy.
- OSA Market Entry Risks: While regulatory and clinical milestones are strong, reimbursement ambiguity and coding challenges could delay or limit initial commercial ramp.
- Innovation Execution: Success of PolySync and next-gen device launches will determine Livanova’s ability to differentiate in both core and adjacent markets.
- External Cost Pressures: Middle East conflict and tariffs are being proactively managed, but logistics and energy costs remain a headwind.
Risks
Key risks include ongoing reimbursement uncertainty for OSA, potential delays in manufacturing scale-up, and exposure to macro cost inflation in logistics and energy. The company’s ability to rebuild inventory and manage backorders is reliant on both internal execution and third-party supplier reliability. Additionally, competitive responses in epilepsy and OSA could emerge as new entrants or technologies gain traction.
Forward Outlook
For Q2 2026, Livanova guided to:
- Continued double-digit cardiopulmonary output growth as new manufacturing line ramps in H2.
- Epilepsy volume and pricing tailwinds from improved reimbursement and clinical evidence.
For full-year 2026, management raised guidance:
- Revenue growth of 7% to 8% (constant currency), up from 6% to 7% prior.
- Adjusted EPS of $4.20 to $4.30, reflecting 9% growth at midpoint.
- Free cash flow of $160M to $180M, with $120M capital spend focused on manufacturing expansion and IT.
Management highlighted:
- Persistent demand-supply imbalance in oxygenators, with opportunity for further upside if component availability improves.
- Volume-driven growth in epilepsy expected to materialize in the second half as pipeline and account expansion efforts take hold.
Takeaways
Livanova’s Q1 performance validates its dual playbook of operational execution and pipeline investment, with both core and future growth vectors advancing in parallel. Margin stability and cash discipline support its investment cycle, but successful OSA commercialization and continued market share expansion are essential for sustaining the current valuation.
- Capacity Expansion Drives Share Gains: The company’s aggressive manufacturing investments and competitor exits are reshaping the cardiopulmonary landscape in its favor.
- Epilepsy Positioned for Penetration: U.S. reimbursement and clinical data are enabling both pricing power and eventual step-change in procedure volumes.
- OSA Launch Execution Is Pivotal: Timely resolution of reimbursement and robust commercial rollout will determine if OSA becomes a breakout margin and growth driver by 2028.
Conclusion
Livanova’s Q1 2026 results underscore a business at the intersection of operational leverage and innovation-driven expansion. With raised guidance and strong execution across segments, the company is well-positioned, but must deliver on pipeline launches and navigate external risks to sustain momentum.
Industry Read-Through
Livanova’s manufacturing-led share gains in cardiopulmonary signal a shift in competitive dynamics for medtech players reliant on mature procedure volumes. The company’s success in leveraging reimbursement changes and clinical evidence in neuromodulation highlights the importance of payer engagement and data-driven adoption for device makers. For OSA and other high-growth adjacencies, regulatory clearance alone is insufficient—commercial readiness, coding clarity, and digital health integration will separate winners from laggards. Broader medtech peers should watch Livanova’s approach to capacity, pricing, and digital platforms as leading indicators for durable growth in a cost-conscious, outcome-driven market.